Eden Radioisotopes is a US startup developing a small non-power open-pool reactor of 1.8 MWt using low-enriched uranium to produce medical radioisotopes — primarily molybdenum-99 (Mo-99) and lutetium-177 (Lu-177), plus iodine-131. The company filed an NRC construction permit application in 2026. The US has lacked a reliable domestic Mo-99 source for decades — it is used in approximately 40,000 diagnostic imaging procedures daily in the US. With a 66-hour half-life, Mo-99 cannot be stockpiled and any supply disruption immediately affects healthcare. Eden is developing a medical isotope production facility in Lea County, New Mexico, using a 1.8-megawatt thermal reactor to irradiate targets for radioisotopes used in medical imaging and cancer treatment; the NRC accepted its construction permit application for review on June 16, 2026. (Founded in 2013 and licensed Sandia's Mo-99 reactor concept that November, per Sandia's 2014 news release; an earlier record said 2022.)
Private investors